Last reviewed · How we verify
Propafenone i.v.
Propafenone i.v. is a Class IC antiarrhythmic agent Small molecule drug developed by Charles University, Czech Republic. It is currently FDA-approved for Atrial fibrillation (maintenance of sinus rhythm), Paroxysmal supraventricular tachycardia, Ventricular arrhythmias. Also known as: Antiarrhythmic therapy.
Propafenone is a Class IC antiarrhythmic agent that blocks cardiac sodium channels to slow conduction velocity and suppress abnormal electrical activity in the heart.
Propafenone i.v. is used to treat supraventricular arrhythmia and septic shock, as per clinical trials. Its mechanism of action is as a class Ic antiarrhythmic agent, according to ChEMBL.
At a glance
| Generic name | Propafenone i.v. |
|---|---|
| Also known as | Antiarrhythmic therapy |
| Sponsor | Charles University, Czech Republic |
| Drug class | Class IC antiarrhythmic agent |
| Target | Cardiac sodium channel (Nav1.5) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Propafenone inhibits the fast inward sodium current in cardiac tissue, which decreases the rate of depolarization and slows conduction through the atria and ventricles. This sodium channel blockade also has weak beta-blocking and calcium channel blocking properties. The net effect is suppression of ectopic arrhythmias and stabilization of abnormal cardiac rhythms.
Approved indications
- Atrial fibrillation (maintenance of sinus rhythm)
- Paroxysmal supraventricular tachycardia
- Ventricular arrhythmias
Common side effects
- Dizziness
- Headache
- Nausea
- Blurred vision
- Proarrhythmic effects
- Bradycardia
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propafenone i.v. CI brief — competitive landscape report
- Propafenone i.v. updates RSS · CI watch RSS
- Charles University, Czech Republic portfolio CI
Frequently asked questions about Propafenone i.v.
What is Propafenone i.v.?
How does Propafenone i.v. work?
What is Propafenone i.v. used for?
Who makes Propafenone i.v.?
Is Propafenone i.v. also known as anything else?
What drug class is Propafenone i.v. in?
What development phase is Propafenone i.v. in?
What are the side effects of Propafenone i.v.?
What does Propafenone i.v. target?
Related
- Drug class: All Class IC antiarrhythmic agent drugs
- Target: All drugs targeting Cardiac sodium channel (Nav1.5)
- Manufacturer: Charles University, Czech Republic — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation (maintenance of sinus rhythm)
- Indication: Drugs for Paroxysmal supraventricular tachycardia
- Indication: Drugs for Ventricular arrhythmias
- Also known as: Antiarrhythmic therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing